MDGL250516C460000
- 2.41
- 0.000.00%
Madrigal Pharmaceuticals Newsroom
Madrigal Pharmaceuticals: Strong Financial Performance and Strategic Positioning Justify Buy Rating
JMP Securities Reaffirms Their Buy Rating on Madrigal Pharmaceuticals (MDGL)
Cantor Fitzgerald Maintains Madrigal Pharmaceuticals(MDGL.US) With Hold Rating
Evercore Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $392
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Pfizer (PFE) and Madrigal Pharmaceuticals (MDGL)
JMP Securities Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $443
Madrigal Pharmaceuticals Analyst Ratings
TD Cowen Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $390
TD Cowen Remains a Buy on Madrigal Pharmaceuticals (MDGL)
Jefferies Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $398
TD Cowen Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $390
TD Cowen Sticks to Their Buy Rating for Madrigal Pharmaceuticals (MDGL)
A Quick Look at Today's Ratings for Madrigal Pharmaceuticals(MDGL.US), With a Forecast Between $405 to $475
B. Riley Upgrades Madrigal Pharmaceuticals to Buy From Neutral, Raises Price Target to $422 From $236
Citigroup Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $469
Analysts Offer Insights on Healthcare Companies: Schrodinger (SDGR), Madrigal Pharmaceuticals (MDGL) and Ligand Pharma (LGND)
A Quick Look at Today's Ratings for Madrigal Pharmaceuticals(MDGL.US), With a Forecast Between $239 to $469
Madrigal Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Madrigal Pharmaceuticals Analyst Ratings
Buy Rating for Madrigal Pharmaceuticals Driven by Strong Financials and Promising Clinical Trial Results